

MEMORANDUM

From: Director, MSD **To:** Secretary, Expert Committee on the Selection and Use of Essential Medicines **Date:** 12 January 2007

Our ref: EML 2007 **Attention:** Dr S. Hill

Your ref: E/19/81/15 **Through:** J.M. Bertolote, Coordinator MBD *MB*

Originator: Tarun Dua **Subject:** APPLICATION FOR A PAEDIATRIC FORMULATION FOR CARBAMAZEPINE, SODIUM VALPROATE AND PHENYTOIN TO BE ADDED TO THE WHO MODEL LIST OF ESSENTIAL MEDICINES

Based on both the application prepared by the Royal Liverpool Children's NHS Trust, Eaton Road, Liverpool, UK and our own experience, we have the following comments to offer on the abovementioned subject:

1. The stability and bioavailability of liquid formulations needs to be clearly demonstrated for all the above three paediatric formulations before inclusion.
2. For any liquid formulation of the above three drugs, there should be only one strength included in the essential list.

B. Saraceno
Dr B. Saraceno

Received in PAR 15 JAN 2007

To	Intls	Date	Away
CO	CO	15/1	15/1
SH	SH	15/1	15/1

action needed:

action taken: